Get 20% lifetime commission for referring investors to digrin.com
here.
Zentalis Pharmaceuticals, Inc. (ZNTL) Financials
ZNTL Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 215.3 million | 71.7 million |
| March 31, 2026 | 253.1 million | 70.4 million |
| Dec. 31, 2025 | 289.0 million | 72.8 million |
| Sept. 30, 2025 | 327.3 million | 74.4 million |
ZNTL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -70.2 million | 6.4 million |
| March 31, 2026 | -33.0 million | 3.2 million |
| Dec. 31, 2025 | -30.9 million | 3.1 million |
| Sept. 30, 2025 | -27.0 million | 4.8 million |
ZNTL Net Income
No data available :(
ZNTL Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 174.6 million | - | 33.6 million |
| March 31, 2026 | 211.8 million | 34.7 million | 34.7 million |
| Dec. 31, 2025 | 245.9 million | - | 35.7 million |
| Sept. 30, 2025 | 280.7 million | - | 40.5 million |
ZNTL Shares Outstanding
ZNTL Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 34000 | 63.9 million | 18.4 million | - |
| March 31, 2026 | 34000 | 28.7 million | 9.0 million | -151000 |
| Dec. 31, 2025 | - | 29.5 million | 7.9 million | - |
| Sept. 30, 2025 | - | 23.0 million | 10.8 million | - |
ZNTL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | 151000 |
| Dec. 31, 2025 | - | 157000 |
| Sept. 30, 2025 | - | - |
ZNTL
Price: $2.13
52 week price:
Earnings Per Share: -1.94 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 349136
Market Capitalization: 190.8 million